28 Recruiting Acute Myeloid Leukemia Clinical Trials in Houston
Explore active acute myeloid leukemia research studies enrolling participants across Texas near Houston. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Recruiting Acute Myeloid Leukemia Studies
🔵 Active, Not Recruiting Early Phase1 🩺 Clinical Procedure Protocol
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 🧠 Behavioral & Psychological Program
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
📍 Texas Children's Hospital — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟡 Not Yet Recruiting Phase1 💊 Investigational Drug / Biologic
Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
📍 UT MD Anderson — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Early Phase1 💊 Investigational Drug / Biologic
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
📍 Texas Children's Cancer and Hematology Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
📍 MD Anderson — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Phase I Study of HC-7366 for Acute Myeloid Leukemia
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
📍 MD Anderson — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔